Hanmi Science's subsidiary Hanmi Pharmaceutical said it will cancel 85,316 treasury shares it holds on November 2, 2026, as disclosed on October 27, 2026.

Hanmi Science's subsidiary Hanmi Pharmaceutical decided at its board meeting on October 27, 2026 to cancel 85,316 treasury shares it holds. The planned cancellation amount is KRW 28.3 billion, and the planned cancellation date is November 2, 2026. The company said the cancellation will be carried out by a board resolution without a capital reduction procedure.

1. 01

   The shares to be cancelled are treasury shares that the subsidiary Hanmi Pharmaceutical has already acquired and holds.

2. 02

   The company said it will cancel the shares by a resolution of the board of directors, without a capital reduction procedure, under the proviso of paragraph 1 of Article 343 of the revised Commercial Act.

3. 03

   The planned cancellation amount is based on the book value of the shares to be cancelled, and the planned cancellation date may change depending on consultations with relevant authorities and other factors.

4. 04

   The company said this disclosure replaces a disposal disclosure for treasury shares.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Common shares to be cancelled

85,316 shares

Planned cancellation amount

KRW 28.3 billion

Value per share

KRW 2,500

Total common shares issued

12,810,991 shares

Planned cancellation date

November 2, 2026

Filing facts

Filing type

Share Cancellation

Report name

Decision on Share Cancellation (Subsidiary)

Filed

Oct 27, 2026

Receipt number

20261027800671